돌연변이 p53 단백질의 Silencing에 의한 사람유방암세포의 in vivo 항종양 효과
Mutant p53 (R280K) is highly expressed in MDAMB- 231 triple-negative human breast cancer cells. Currently, we reported the role of mutant p53-R280K in mediating the survival of MDA-MB-231 cells in vitro. The present study was undertaken to determine whether mutant p53-R280K affects breast cancer cel...
Saved in:
Published in | KSBB Journal Vol. 31; no. 1; pp. 52 - 57 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | Korean |
Published |
한국생물공학회
01.03.2016
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Mutant p53 (R280K) is highly expressed in MDAMB- 231 triple-negative human breast cancer cells. Currently, we reported the role of mutant p53-R280K in mediating the survival of MDA-MB-231 cells in vitro. The present study was undertaken to determine whether mutant p53-R280K affects breast cancer cell growth in vivo. To this end, we used small interfering RNA to knockdown the level of mutant p53- R280K in MDA-MB-231 cells. Silencing of mutant p53- R280K in MDA-MB-231 cells causes substantial tumor regression of established xenografts in vivo. In xenograft model for breast cancer, silencing of mutant p53-R280K in MDAMB- 231 cells significantly inhibited the tumor growth. Moreover, TUNEL assay showed more occurrence of apoptotic cells in mutant p53-R280K silenced tumors compared to control.
Our data indicate that mutant p53-R280K has an important role in mediating tumor growth of MDA-MB-231 cells in vivo. Taken together, this study suggests that endogenous mutant p53-R280K could be used as a therapeutic target for breast cancer cells harboring this TP53 missense mutation. KCI Citation Count: 0 |
---|---|
Bibliography: | G704-SER000001461.2016.31.1.003 |
ISSN: | 1225-7117 2288-8268 |
DOI: | 10.7841/ksbbj.2016.31.1.52 |